A Phase I study to evaluate the safety and efficacy of L19IL2 in combination with ruxolitinib in patients with advanced solid tumors.

2025-522243-17-00 · tracked via the Priya Life Science EU tracker

Sponsor

Philogen S.p.A.

Sponsor type

Pharmaceutical company

Therapeutic area

Neoplasms

Decision date

22/12/2025

Enrollment target

Sites

Italy

Condition studied

Advanced solid tumors, specifically: • metastatic clear cell renal carcinoma • proficient mismatch repair / microsatellite stable (pMMR/MSS), BRAF-V600E-mutant negative colorectal carcinoma • locally advanced or metastatic pancreatic adenocarcinoma

Eligibility

Age group

65+ years, 18-64 years

Sex

Female, Male

Official registry record

This page summarises publicly available CTIS data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View 2025-522243-17-00 on CTIS ↗ ← All trials in the EU